14
Cat No. | Product Name | Synonyms | Targets |
---|---|---|---|
T8467 | RET V804M-IN-1 | RETV804M kinase inhibitor,LUN09945 | c-RET |
RET V804M-IN-1 (RETV804M kinase inhibitor) is a wt-RET -selective RETV804M kinase inhibitors(IC50 = 20 nM). | |||
T16735 | RET-IN-1 | Others | |
RET-IN-1 is a RET kinase inhibitor (IC50s: 1 nM, 7 nM, and 101 nM for RET (WT), RET (V804M) , and RET (G810R), respectively). | |||
T64103 | RET-IN-12 | ||
RET-IN-12 is a RET inhibitor capable of acting on RET(WT) (IC50: 0.3 nM) and RET(V804M) (IC50: 1 nM). | |||
T81296 | RET-IN-26 | ||
RET-IN-26 (compound D5) is a kinase inhibitor that selectively targets the RET protein with an IC50 value of 0.33 μM [1]. | |||
T79163 | RET-IN-24 | ||
RET-IN-24 (Compound 26) is a selective inhibitor of RET tyrosine kinase, demonstrating antitumor activity [1]. | |||
T79099 | RET-IN-23 | ||
RET-IN-23 (compound 17) is a potent, orally active inhibitor of RET, displaying IC50 values of 1.32 nM for RET-WT, 2.50 nM for RET-CCDC6, 6.54 nM for RET-V804L, 1.03 nM for RET-V804M, and 1.47 nM for RET-M918T. The compo... | |||
T78683 | RET-IN-22 | ||
RET-IN-22 (compound 17b) is a potent, selective, and orally active inhibitor of RET, exhibiting IC50 values of 20.9 nM for wild-type RET and 18.3 nM for RET-V804M. It demonstrates a highly selective inhibition profile ac... | |||
T79726 | RET-IN-25 | ||
RET-IN-25 (compound 6b) is an anticancer RET kinase inhibitor that demonstrates efficacy against medullary thyroid carcinoma (MTC), exhibiting half-maximal inhibitory concentrations (IC50s) of 3.6 μM at 3 days and 3.0 μM... | |||
T77646 | Multi-kinase-IN-5 | ||
Multi-kinase-IN-5 (compound 15c) is a multi-kinase inhibitory agent that shows significant inhibition against a range of protein kinases including RET, KIT, cMet, VEGFR1, VEGFR2, FGFR1, PDGFR, and BRAF, with correspondin... | |||
T1656L | Vandetanib Fumarate | HSDB 8198,Zactima,Caprelsa,ZD 6474,Vandetanib | |
Vandetanib Fumarate is an orally available tyrosine kinase inhibitor. Vandetanib Fumarate works by blocking RET (REarranged during Transfection), vascular endothelial growth factor receptor (VEGFR-2, VEGFR-3), and epider... | |||
T73033 | TRK II-IN-1 | Trk receptor | |
TRK II-IN-1 is a potent type II inhibitor of tropomyosin receptor kinases (TRK), demonstrating inhibitory half-maximal inhibitory concentrations (IC50s) of 3.3, 6.4, 4.3, and 9.4 nM against TRKA, TRKB, TRKC, and the muta... | |||
T78871 | PLM-101 | ||
PLM-101 is an anticancer compound orally active against acute myeloid leukemia by targeting FLT3 and RET. It impedes RET function, promoting autophagic breakdown of FLT3, and suppresses the PI3K and Ras/ERK pathways, con... | |||
T78203 | NSC194598 | ||
NSC194598 is a p53 DNA-binding inhibitor, demonstrating an in vitro IC50 of 180 nM and an in vivo range of 2-40 μM. It disrupts the transcriptional activation of the mutated RET gene in human medullary thyroid carcinoma ... | |||
T37582 | Ganglioside GM1 Mixture (ovine) (ammonium salt) | ||
Ganglioside GM1is a monosialylated ganglioside and the prototypic ganglioside for those containing one sialic acid residue.1,2It is found in a large variety of cells, including immune cells and neurons, and is enriched i... |